Abstract:Growth Hormone Releasing Hormone (GHRH) is one of the most important hormones in life. Because of its potential clinical importance, its short half-life, and its expensive chemical synthesis, an analog of hGHRH with a prolonged half-life and better activity has been studied for clinical application, especially for the treatment of muscle wasting, type II diabetes, or sleep disorders. The Pro–Pro–hGHRH(1–44) peptide has better activity. The fusion partner gene with 127 amino acid residues of the C-terminus from l-asparaginase was recombined with asp-pro–pro–hGHRH(1–44) gene synthesized by PCR method to form a fusion protein with the unique acid labile linker Asp–Pro. The recombinant protein was expressed to high levels in Escherichia coli BL21 (DE3). The Pro–Pro–hGHRH(1–44) peptide was purified to homogeneity by means of cell disruption, washing, ethanol precipitation, acid hydrolysis, and SP-Sephadex C-25, and Sephadex G-25 column chromatography. The fold of the purification was about 88 times and the yield was 1.1% of the total protein weight of the inclusion body. The peptide molecular mass of 5235.25Da was determined by ESI mass spectroscopy. Its purity was determined by SDS–PAGE. In the study of the activity, we measured GH release of rat pituitary by using the antiserum kit against human GH. The peptide doses of 0.01, 0.1, 1.0, 7.72, and 20.9μg/ml used, respectively, released the GH values of 0.1±0.1, 12.5±7.3, 16.6±5.8, 49.8±7.6, and 79.5±5.7ng/ml whereas their blank controls, respectively, were 0.5±0.8, 4.1±2.6, 3.1±3.1, 4.7±1.8, and 1.2±0.3ng/ml. The activity results of all dose groups except 0.01μg/ml Pro–Pro–hGHRH(1–44) group and hGHRH(1–40) group showed that there were significant differences between GH released by the peptide and that by its blank control. With the increase of dosage, the differences were more significant. hGHRH(1–40) showed no measured GH release when the dose was up to 2μg/ml. The activity results show that the Pro–Pro–hGHRH(1–44) peptide is a potential GH releasing analog.

Structure and function relationships of three novel hGHRH-GGC analogs

Study on the Constructions and Activities of Three Novel Hghrh Analogs with N-terminal Prolyl Modulation+

A Novel Hghrh Analog and Its Comparative Activity

Production and enhanced biological activity of a novel GHRH analog, hGHRH with an N-terminal Pro-Pro extension.

Recombination and Comparable Activity of A Novel Hghrh Analogs,Pro-hGHRH(1-44)-Gly-Gly-Cys

Construction and Activity of A Novel Ghrh Analog, Pro-,Pro-Hghrh(1-44)-Gly-Gly-Cys

In Vivo Bioassay of Recombinant Human Growth Hormone Synthesized Inb. Moripupae

Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities.

High-level secretory expression, purification and characterization of Ailuropoda melanoleuca growth hormone in Pichia pastoris.

Expression, Purification, And Lipolytic Activity Of Recombinant Human Serum Albumin Fusion Proteins With One Domain Of Human Growth Hormone In Pichia Pastoris

Structural Basis for Activation of the Growth Hormone-Releasing Hormone Receptor.

Synthetic analogs of growth hormone-releasing factor with antagonistic activity in vitro.

Recent Advances in the Biological Function of Ghrelin

Growth hormone secretagogues and their structure-activity relationship

GHRH and the prostate

Growth hormone-releasing hormone and its analogues in health and disease

Characterisation of the 5kda Growth Hormone Isoform

Molecular Recognition of an Acyl-Peptide Hormone and Activation of Ghrelin Receptor

The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders

Ectopic Co-expression of Growth Hormone Releasing Hormone and Pituitary Adenylate Activating Peptide in Skeletal Muscle Enhance Animal Growth*

Spiro(indoline-3,4'-piperidine) growth hormone secretagogues as ghrelin mimetics